Christopher Harbison

40.1k total citations · 10 hit papers
63 papers, 9.4k citations indexed

About

Christopher Harbison is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Christopher Harbison has authored 63 papers receiving a total of 9.4k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Oncology, 38 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Christopher Harbison's work include Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Treatments and Mutations (26 papers) and Colorectal Cancer Treatments and Studies (24 papers). Christopher Harbison is often cited by papers focused on Cancer Immunotherapy and Biomarkers (38 papers), Lung Cancer Treatments and Mutations (26 papers) and Colorectal Cancer Treatments and Studies (24 papers). Christopher Harbison collaborates with scholars based in United States, Italy and Germany. Christopher Harbison's co-authors include Richard A. Young, Tong Ihn Lee, Nancy M. Hannett, Julia Zeitlinger, David K. Gifford, Eric S. Lander, Ezra G. Jennings, Dmitry Pokholok, Scott Gettinger and Nicola J. Rinaldi and has published in prestigious journals such as Nature, Cell and Journal of Clinical Oncology.

In The Last Decade

Christopher Harbison

62 papers receiving 9.2k citations

Hit Papers

Transcriptional regulatory code of a eukaryotic genome 2001 2026 2009 2017 2004 2005 2001 2007 2001 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Transcriptional regulatory code of a eukaryotic genome
    2004 1.7k citations Christopher Harbison, Tong Ihn Lee et al. Nature profile →
  2. Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast
    2005 1.1k citations Dmitry Pokholok, Christopher Harbison et al. Cell profile →
  3. Remodeling of Yeast Genome Expression in Response to Environmental Changes
    2001 1.1k citations Christopher Harbison, Ezra G. Jennings et al. profile →
  4. Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab
    2007 898 citations Shirin Khambata‐Ford, Christopher R. Garrett et al. Journal of Clinical Oncology profile →
  5. Serial Regulation of Transcriptional Regulators in the Yeast Cell Cycle
    2001 503 citations Itamar Simon, Nancy M. Hannett et al. Cell profile →
  6. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer
    2018 471 citations Yelena Y. Janjigian, Johanna C. Bendell et al. Journal of Clinical Oncology profile →
  7. Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non–Small Cell Lung Cancer Treated With Nivolumab
    2019 409 citations Julie R. Brahmer, Scott Gettinger et al. profile →
  8. Nivolumab Monotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    2016 394 citations Scott Gettinger, Naiyer A. Rizvi et al. Journal of Clinical Oncology profile →
  9. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
    2017 362 citations Christopher Harbison et al. profile →
  10. Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
    2016 350 citations Naiyer A. Rizvi, Julie R. Brahmer et al. Journal of Clinical Oncology profile →

Peers

Christopher Harbison
Anja von Heydebreck Germany
Yataro Daigo Japan
Somasekar Seshagiri United States
Asha S. Multani United States
Toyomasa Katagiri Japan
Rugang Zhang United States
Roderick L. Beijersbergen Netherlands
Emma Lees United States
Luc Girard United States
Khandan Keyomarsi United States
Anja von Heydebreck Germany
Christopher Harbison
Citations per year, relative to Christopher Harbison Christopher Harbison (= 1×) peers Anja von Heydebreck

Countries citing papers authored by Christopher Harbison

Since Specialization
Citations

This map shows the geographic impact of Christopher Harbison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Harbison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Harbison more than expected).

Fields of papers citing papers by Christopher Harbison

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher Harbison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Harbison. The network helps show where Christopher Harbison may publish in the future.

Co-authorship network of co-authors of Christopher Harbison

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher Harbison. A scholar is included among the top collaborators of Christopher Harbison based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher Harbison. Christopher Harbison is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lei, Ming, Nathan O. Siemers, Dimple Pandya, et al.. (2021). Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer. Clinical Cancer Research. 27(14). 3926–3935. 57 indexed citations
2.
Janjigian, Yelena Y., Johanna C. Bendell, Emiliano Calvo, et al.. (2018). CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. Journal of Clinical Oncology. 36(28). 2836–2844. 471 indexed citations breakdown →
3.
Ott, Patrick A., Dung T. Le, Paolo A. Ascierto, et al.. (2017). Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032. Annals of Oncology. 28. v229–v230. 9 indexed citations
4.
5.
Rosenberg, Jonathan E., Petri Bono, Pavlina Spiliopoulou, et al.. (2016). Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study. Annals of Oncology. 27. vi271–vi271. 2 indexed citations
6.
Sharma, Padmanee, Petri Bono, Joseph W. Kim, et al.. (2016). Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.. Journal of Clinical Oncology. 34(15_suppl). 4501–4501. 37 indexed citations
7.
8.
Abdel‐Motal, Ussama M., Christopher Harbison, Tao Han, et al.. (2014). Prolonged expression of an anti-HIV-1 gp120 minibody to the female rhesus macaque lower genital tract by AAV gene transfer. Gene Therapy. 21(9). 802–810. 12 indexed citations
9.
Antonia, Scott, Scott Gettinger, Laura Q.M. Chow, et al.. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.. Journal of Clinical Oncology. 32(15_suppl). 8023–8023. 118 indexed citations
10.
Rizvi, Naiyer A., Laura Q.M. Chow, Hossein Borghaei, et al.. (2014). Safety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLC.. Journal of Clinical Oncology. 32(15_suppl). 8022–8022. 99 indexed citations
11.
Soria, Jean‐Charles, José Baselga, Nasser H. Hanna, et al.. (2013). Phase I–IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. European Journal of Cancer. 49(8). 1815–1824. 16 indexed citations
12.
Denne, Jonathan, Luping Zhao, Christine E. Horak, et al.. (2013). Comparison of KRAS Genotype: Therascreen Assay vs. LNA-Mediated qPCR Clamping Assay. Clinical Colorectal Cancer. 12(3). 195–203.e2. 5 indexed citations
13.
Jonker, Derek J., Christos S. Karapetis, Christopher Harbison, et al.. (2013). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer. 110(3). 648–655. 64 indexed citations
14.
Baker, Joffre, Debjani Dutta, Drew Watson, et al.. (2011). Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. British Journal of Cancer. 104(3). 488–495. 81 indexed citations
15.
Christopher, Lisa J., Haizheng Hong, Blisse Vakkalagadda, et al.. (2010). Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans. Drug Metabolism and Disposition. 38(11). 2049–2059. 16 indexed citations
16.
Garrett, Christopher, Edwin Clark, Mark Basik, et al.. (2007). Expression of epiregulin and amphiregulin and K-RAS mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab (Erbitux ®). Cancer Research. 67. 5670–5670. 3 indexed citations
17.
Khambata‐Ford, Shirin, Christopher R. Garrett, Neal J. Meropol, et al.. (2007). Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab. Journal of Clinical Oncology. 25(22). 3230–3237. 898 indexed citations breakdown →
18.
Pokholok, Dmitry, Christopher Harbison, Stuart S. Levine, et al.. (2005). Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast. Cell. 122(4). 517–527. 1098 indexed citations breakdown →
19.
Harbison, Christopher, Tong Ihn Lee, Nicola J. Rinaldi, et al.. (2004). Transcriptional regulatory code of a eukaryotic genome. Nature. 431(7004). 99–104. 1653 indexed citations breakdown →
20.
Zeitlinger, Julia, Itamar Simon, Christopher Harbison, et al.. (2003). Program-Specific Distribution of a Transcription Factor Dependent on Partner Transcription Factor and MAPK Signaling. Cell. 113(3). 395–404. 186 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Anja von Heydebreck Breakdown of academic impact, for papers by Yataro Daigo Breakdown of academic impact, for papers by Somasekar Seshagiri Breakdown of academic impact, for papers by Asha S. Multani Breakdown of academic impact, for papers by Toyomasa Katagiri Breakdown of academic impact, for papers by Rugang Zhang Breakdown of academic impact, for papers by Roderick L. Beijersbergen Breakdown of academic impact, for papers by Emma Lees Breakdown of academic impact, for papers by Luc Girard Breakdown of academic impact, for papers by Khandan Keyomarsi
Rankless by CCL
2026